As Omicron strikes, 87% of life sciences sector held back by too-slow data movement

The Omicron variant is making its way across the world. Tracking cases and speeding up booster jabs is critical.

However, expert research has revealed a shocking 87% of life science companies are facing operational challenges from a lack of investment in data movement. This puts them on the back foot, making on-the-fly decisions with outdated information, hindering vaccine development and rollout.

In a global first, Solace’s survey of 840 IT professionals reveals that just 17% of life science and healthcare have succeeded in implementing real-time data.

“The health space must implement technologies to allow multiple digital systems to talk to each other in real time, including supply chain, product lifecycle management, quality control, manufacturing and others.” says Jamil Ahmed, Distinguished Engineer at Solace.

To view the full report, click here.